: iStockAnalyst.com Symbols Feed

Daily Highlights: Sept 3, 2009

Thu, 03 Sep 2009 12:54:51 GMT

Asian stocks gain on Gold, Alcoa forecast; Honda drops on strong Yen.China to buy around $50B in notes denominated in the IMF's quasi-currency.[More...]

Sepracor’s (SEPR) Great Value Recognized By Japan’s Dainippon Sumitomo

Wed, 02 Sep 2009 19:07:40 GMT

Sepracor (SEPR) shares surged up to 30% higher in early afternoon trading as news broke from the Nikkei of an approximately $2.71 billion offer from Dainippon Sumitomo. Sepracor’s stock has been hammered over the last few years, and recently there have been some disappointing clinical trial results.[More...]

Study Of Sepracor’s Depression Drug Has Investors Gloomy

Thu, 02 Jul 2009 18:22:43 GMT

“Big percentage move on the down side out of Sepracor. It is down about 16% in the pre-market this morning… There’s Sepracor, $14.85 big drop as a depression drug that failed in a clinical trial. That’s why that stock is getting hammered ahead of the open.” Fox Business Network Money For Breakfast 7/2/2009 Drug maker Sepracor (SEPR) received some disappointing news today in regards to a clinical trial of a drug used to treat depression. The preliminary study showed that 514 patients taking the drug, called SEP-225289, did not show any significant improvement in[More...]

More Cash, Less Debt = Stock Market Gains?

Thu, 23 Apr 2009 13:41:32 GMT

Today there were a couple of posts about how tech stocks are currently especially attractive because they hold plenty of cash and tend to have little debt. Paul Kedrosky initially caught my eye with his post "Tech Cash is King" which in turn pointed me to a story on Bloomberg by Eric Martin. I ran a screen tonight that looked at both cash and debt. Specifically, I screened for a Price-to-Cash ratio under three, a Debt-to-Equity ratio under three and a Market Cap greater than $2.5 million. Based on these criteria, I obtained a list of 136 stocks. Judging from our list, it is absolutely true that many tech stocks do seem to have lots of cash and little debt. What also became apparent as I went through the list is that there[More...]

54 Stocks Returning 15%+ in January

Sun, 01 Feb 2009 18:18:00 GMT

As we exit the worst January ever, I thought it would be interesting to take a look at the best performers of the past month. Before we do, courtesy of Dshort.com this is a chart that has been passed around a lot in the investing community so I thought I'd share it. Two ways to read this - of the 4 great bear markets the past 100 years, 3 "ended" roughly where we are now... about a 50% loss in value from peak. That's the bullish view i.e. "can't get worse than this" and if we fall to S&P 750 (November lows) but never break through they will be correct. The bearish view is - the 4th bear market ended in a 90% drop, and if you plot the velocity of the decline, what happened to us in Sep - Nov caused us to be in lockstep with the worst of the 4. I'm not calling for a 90% drop[More...]

Pharmaceuticals Industry

Fri, 21 Nov 2008 20:17:00 GMT

Names that were previously viewed as safe and stable investments, large-cap pharmaceuticals, are now trading at levels not seen since 2002.? And, for some such as Pfizer, Inc. (PFE) and Eli Lilly & Co. (LLY), these are prices not seen since the past decade. This is clearly a sell-first, ask questions later market. After all, believing that patients are going to stop taking Bristol-Myers Squibb Co. (BMY) blood-thinner Plavix or Pfizer's anti-cholesterol agent Lipitor because of the credit crunch is the epitome of irrational anxiety. [More...]

Sepracor Putting Cash to Work - Analyst Blog

Wed, 29 Oct 2008 15:31:00 GMT

Sepracor Inc. (SEPR), headquartered in Marlborough, Massachusetts, is a research-based pharmaceutical company focused on the treatment of respiratory and central nervous system disorders. The company's business fundamentals have been mixed over the past several quarters. Lunesta growth has been a disappointment, and with several new sleep medications coming to the market in the next few years, we see little that can be done to re-accelerate trends in the U.S. As such, we find it hard to believe Sepracor's stock will outperform while Lunesta treads water. Thankfully, we are pleased to see management looking to move beyond Lunesta and expanding its respiratory franchise with the recent additions or two new products and several technology licensing deals. Additionally, the mid-stage pipeline is progressing nicely. Near term, the best opportunity to[More...]

Analyst Comments: Cooper Tire, Sony Corporation, Sepracor, HealthSouth, Edison International

Fri, 01 Aug 2008 13:13:00 GMT

A challenging North American auto environment, elevated raw material costs, and strong competition make us rate Cooper Tire & Rubber Company (CTB) a Sell with a six-month target price of $7.00.[More...]

Analyst Comments: Lockheed, National Beverage, STMicroelectronics, Nortel, DeVry, Sepracor, American Electric

Mon, 16 Jun 2008 23:34:33 GMT

We maintain a Buy recommendation for Lockheed Martin Corp. (LMT) as the company appears well-positioned to continue to benefit from strong defense outlays through 2008-09. Solid operating results, via existing and new contracts, coupled with the success of its C-130J and F-35 aircraft collectively continue to deliver strong earnings and cash flow growth. The management increased its 2008 per share guidance by $0.10, which supports the bullish outlook. Additionally,...[More...]

May Day

Thu, 01 May 2008 16:30:43 GMT

Good morning. Along with more earnings reports, investors have a lot of mixed economic data to keep them busy ahead of tomorrow's jobs report. At 10:AM we also have reports on construction spending and the ISM.[More...]

Dainippon of Japan acquires US drug maker Sepracor

Thu, 03 Sep 2009 18:46:00 GMT

TOKYO - Dainippon Sumitomo Pharma Co. is acquiring U.S. drug maker Sepracor Inc., which makes insomnia drug Lunesta, for about $2.6 billion in an effort to expand in the U.S. market, both sides said Thursday.
Dainippon said that the acquisition of Sepracor will also increase its overseas revenue to 40 percent of its total.
The company said it will offer $23 per share, a 27.6 percent premium over Sepracor's closing price Tuesday, through a tender offer set to start in early September.

: iStockAnalyst.com Symbols Feed

Daily Highlights: Sept 3, 2009

Sepracor’s (SEPR) Great Value Recognized By Japan’s Dainippon Sumitomo

Study Of Sepracor’s Depression Drug Has Investors Gloomy

More Cash, Less Debt = Stock Market Gains?

54 Stocks Returning 15%+ in January

Pharmaceuticals Industry

Sepracor Putting Cash to Work - Analyst Blog

Analyst Comments: Cooper Tire, Sony Corporation, Sepracor, HealthSouth, Edison International

Analyst Comments: Lockheed, National Beverage, STMicroelectronics, Nortel, DeVry, Sepracor, American Electric

May Day

Dainippon of Japan acquires US drug maker Sepracor

Dainippon Sumitomo to Buy U.S. Drugmaker Sepracor for $2.6 Bil.

Dainippon of Japan acquires US drug maker Sepracor

Stocks Tumble on Jobs News

Elan, NRG Energy, Boeing are big movers

Drugmaker Sepracor cuts 530 jobs to lower costs

Dainippon Sumitomo Pharma Co., Ltd. Completes Acquisition of Sepracor Inc.

Jefferies Expands International Healthcare Investment Banking Platform

Sepracor Announces Expiration of Hart-Scott-Rodino Waiting Period

Levi &Amp; Korsinsky, LLP Announces Class Action Lawsuit Against Sepracor, Inc. -- SEPR

Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Sepracor, Inc.

Dainippon Sumitomo Pharma to Acquire Sepracor for U.S. $23.00 Per Share in an All-Cash Tender Offer Valued at Approximately U.S. $2.6 Billion

BenchmarkJournal.Com Free Analyst Review for ESRX, PDCO, FMCN, SEPR, PETM and CTSH

Sepracor Announces New Drug Submission (NDS) to Health Canada for STEDESA™ as Adjunctive Treatment for Epilepsy

Sepracor Inc. Reports Strong Second Quarter 2009 Operating Results and Increases Financial Guidance for 2009

Sepracor Inc. Sets Conference Call and Webcast for Second Quarter 2009 Operating Results

Form 4 SEPRACOR INC /DE/ For: Oct 20 Filed by: ADAMS ADRIAN (10K)

Form 4 SEPRACOR INC /DE/ For: Oct 20 Filed by: CORRIGAN MARK (10K)

Form 4 SEPRACOR INC /DE/ For: Oct 20 Filed by: Iwicki Mark T (10K)

Form 4 SEPRACOR INC /DE/ For: Oct 20 Filed by: KOVEN ANDREW I (10K)

Form 4 SEPRACOR INC /DE/ For: Oct 20 Filed by: RANIERI RICHARD J (10K)

Form 4 SEPRACOR INC /DE/ For: Oct 20 Filed by: SCUMACI ROBERT F (10K)

Form 4 SEPRACOR INC /DE/ For: Oct 20 Filed by: Sierra Jose (10K)

Form 4 SEPRACOR INC /DE/ For: Oct 20 Filed by: BARBERICH TIMOTHY J (10K)

Form 4 SEPRACOR INC /DE/ For: Oct 20 Filed by: BARRIOS DIGBY (10K)

Form 4 SEPRACOR INC /DE/ For: Oct 20 Filed by: CRESCI ROBERT J (10K)